Vanderbilt

Questions discussed in this category

Outside of a clinical trial, what is your preferred third-line systemic therapy option for a patient with relapsed/refractory ES-SCLC?

1 Answer available

In a life-time non-smoker with stage IV lung adenocarcinoma presenting in visceral crisis, what therapy would you recommend to avoid organ failure while awaiting mutational status?

1 Answer available

What is the optimal treatment strategy for patients with stage IV NSCLC who have an actionable molecular target identified after initiation of first-line systemic therapy?

1 Answer available

For a young patient with small cell bladder cancer, what would you recommend following cisplatin + etoposide, if scans show no evidence of distant disease and repeat TURBT shows no malignancy?

2 Answers available

For persistent localized muscle-invasive bladder cancer following chemoradiation in patients who are not surgical candidates, what is an appropriate next therapy?

2 Answers available

What is your approach to consolidation for localized small cell bladder cancer after neoadjuvant cisplatin and etoposide?

Specifically, for cT2N0M0 small cell bladder cancer without response to neoadjuvant cisplatin and etoposide on imaging, would you proceed with cystect...

1 Answer available

Would you consider checkpoint inhibitor therapy alone in a patient with metastatic NSCLC with PDL-1 < 1% who is otherwise refusing chemotherapy?

Would nivo + Ipi be appropriate in this situation, especially if high TMB?

4 Answers available

What is the role for "liquid biopsy" for patients with newly diagnosed metastatic NSCLC?

Especially in light of the new Guardant data presented at AACR 2019

5 Answers available

With the FDA approval of third line pembrolizumab for patients with SCLC, how would you select a candidate for pembrolizumab or nivolumab in the third line management of SCLC?

1 Answer available

When do you recommend broader molecular testing for clinical trials in stage IV NSCLC patients who have negative initial molecular testing for FDA-approved targetable mutations?

1 Answer available

For pre-menopausal patients with high-risk ER+ disease, and who desire pregnancy, what is the best time frame to pause endocrine therapy to allow for pregnancy?

High enough risk to justify anthracycline+taxane chemotherapy followed by ovarian suppression + aromatase inhibition.

1 Answer available

Papers discussed in this category

N. Engl. J. Med., 2019 Sep 28

Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.

Clinical genitourinary cancer, 2017-06

Small-Cell Carcinoma of the Bladder: 20-Year Single-Institution Retrospective Review.

The Journal of urology, 2014-02

Locoregional small cell carcinoma of the bladder: clinical characteristics and treatment patterns.

European urology focus, 2018-12

Treatment Patterns and Survival Outcomes for Patients with Small Cell Carcinoma of the Bladder.

Int J Radiat Oncol Biol Phys, 2015 Jul 15

Small Cell Carcinoma of the Urinary Bladder: A Retrospective, Multicenter Rare Cancer Network Study of 107 Patients.

Clin Genitourin Cancer, 2019 Mar 28

Prognostic Variables in Patients With Non-metastatic Small-cell Neuroendocrine Carcinoma of the Bladder: A Population-Based Study.

Int J Radiat Oncol Biol Phys, 2021 Feb 06

Treatment Outcomes for Small Cell Carcinoma of the Bladder: Results From a UK Patient Retrospective Cohort Study.

Am Soc Clin Oncol Educ Book,

Checkpoint Blockade in Lung Cancer With Driver Mutation: Choose the Road Wisely.

Ann Oncol, 2013 Mar 01

Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC).

Vanderbilt

Questions discussed in this category

Papers discussed in this category

Related Topics